Prime Medicine Trading Down 4.6 percent Time to Sell?
| PRME Etf | USD 2.65 0.25 8.62% |
About 61% of Prime Medicine,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Prime Medicine, Common suggests that many traders are alarmed. The current market sentiment, together with Prime Medicine,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Prime Medicine, Common etf news signals to limit their universe of possible portfolio assets.
Prime Medicine, etf news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Prime daily returns and investor perception about the current price of Prime Medicine, Common as well as its diversification or hedging effects on your existing portfolios.
Prime |
Prime Medicine, Inc. traded down 4.6 percent on Tuesday . The company traded as low as 4.07 and last traded at 4.17. 325,790 shares changed hands during mid-day trading, a decline of 67 percent from the average session volume of 978,204 shares. The stock had previously closed at 4.37. Analysts Set New
Read at thelincolnianonline.com
 |
Prime Medicine, Fundamental Analysis
We analyze Prime Medicine,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prime Medicine, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prime Medicine, based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Prime Medicine, is currently under evaluation in net asset as compared to similar ETFs. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Prime Medicine, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prime Medicine, etf to make a market-neutral strategy. Peer analysis of Prime Medicine, could also be used in its relative valuation, which is a method of valuing Prime Medicine, by comparing valuation metrics with similar companies.
Peers
Prime Medicine, Related Equities
| RLAY | Relay Therapeutics | 1.90 | ||||
| BPMC | Blueprint Medicines | 0.15 | ||||
| CRSP | Crispr Therapeutics | 0.25 | ||||
| RPRX | Royalty Pharma | 0.92 | ||||
| EDIT | Editas Medicine | 1.08 | ||||
| IPSC | Century Therapeutics | 1.43 | ||||
| CRBU | Caribou Biosciences | 3.13 | ||||
| BEAM | Beam Therapeutics | 6.53 | ||||
| NTLA | Intellia Therapeutics | 6.95 | ||||
| VERV | Verve Therapeutics | 8.25 | ||||
| SANA | Sana Biotechnology | 10.07 | ||||
| DNA | Ginkgo Bioworks | 11.47 |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.